TTThierry Trenque

Thierry Trenque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thierry Trenque has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Brahim Azzouz

    Université de Reims Champagne-Ardenne, VIEFRA, CHU de Reims, Centre Régional de Pharmacovigilance de Reims, Reims, France

    6 shared publications
  • Emmanuelle Herlem

    Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital 51100 Reims France

    5 shared publications
  • Paul de Boissieu

    Centre régional de pharmacovigilance et de pharmaco-épidémiologie de Champagne-Ardenne, CHU de Reims, 51092 Reims, France; EA 3797, faculté de médecine, université de Reims Champagne-Ardenne, 51100 Reims, France

    5 shared publications
  • Agathe Trenque

    Reims University Hospitals, Regional Centre for Pharmacovigilance and Pharmacoepidemiology, 51092 Reims, France

    4 shared publications
  • Aurore Morel

    Regional Centre of Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Reims France

    4 shared publications
  • H. Millart

    Laboratoire de Pharmacologie‐Toxicologie, CHU, Reims

    4 shared publications

Latest Publications

  • Open Access

    Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database

    by Salomé Martin, Thierry Trenque, Emmanuelle Herlem, Charlène Boulay, Véronique Pizzoglio, Brahim Azzouz

    Aims: Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration.Methods: To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non‐case study on reports of ‘acute febrile neutrophilic dermatosis’ registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated.Results: Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15–91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1–1095). The highest RORs were observed with bortezomib (74.04 [40.8–134.2]), azacitidine (72.14 [29.4–176.9]), perfilgrastim (67.05 [21.2–211.6]), azathioprine (55.46 [34.8–88.4]) and bendamustine (35.84 [11.4–112.8]).Conclusions: Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony‐stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug‐induced Sweet's syndrome.


  • Statins and immune-mediated necrotizing myopathy: Variability in the risk

    by Thierry Trenque, Jed Hadjoudj, Agathe Trenque, Federica Tralongo, Salomé Martin, Brahim Azzouz


  • Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals

    by Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque


  • Psoriasis risk after beta‐blocker exposure: Description of a pharmacovigilance signal

    by Brahim Azzouz, Apolline De Guizelin, Aude Lambert, Audrey Fresse, Aurore Morel, Thierry Trenque

    Aim: We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta‐blocker (BB) exposure and bring to light a possible pharmacovigilance signal.Methods: Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case/noncase study.Results: Two hundred and twenty‐five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5 months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75‐10.33).Conclusion: We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.


  • Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity

    by Thierry Trenque, Elise Lepoix, Agathe Trenque, Aurore Morel, Brahim Azzouz

    Purpose Pembrolizumab is a humanized monoclonal antibody that binds to the programmed cell-death protein-1 (PD-1) on immune T-cells, thus blocking PD-1 activity. Pembrolizumab is indicated for the treatment of advanced melanoma, metastatic non-small-cell lung cancer, and head and neck squamous cell carcinoma. However, it is associated with immune-related adverse events. Methods We investigated the association between pembrolizumab and immune-mediated necrotizing myopathy (IMNM). We analyzed reports in the World Health Organization’s global individual case safety report database, Vigibase, up to January 2020 with the MedDRA lower level term “IMNM.” The association between exposure to pembrolizumab and occurrence of the adverse event was estimated by disproportionality analysis. The reporting odds ratio (ROR) was calculated with 95% confidence intervals (CIs). We analyzed the criteria of diagnosis of the adverse reaction. Results Five-hundred sixty-seven notifications were identified as IMNM of which 14 with pembrolizumab. The ROR was 17.59 (95% CI: 9.4–32.9). Conclusion The diagnosis of IMNM does not always take into account recent criteria for the diagnosis of this pathology. This study highlights the existence of a signal, as well as the need for collaboration between oncologists and neurologists for these neurological pathologies.


  • Bismuth and pharmacovigilance

    by Thierry Trenque

  • Drug induced stuttering: pharmacovigilance data

    by Thierry Trenque, Aurore Morel, Agathe Trenque, Brahim Azzouz

    Background: Stuttering is a speech disorder characterized by poor fluency of speech despite the speech production organs being normal. Numerous factors contribute to stuttering, and it may also be an iatrogenic effect of certain drugs. The aim of this study was to investigate the association between stuttering and drug exposure. Research design and methods: We investigated the association between drugs and stuttering. We analyzed reports in the World Health Organization global individual case safety reports database (Vigibase) up to 31 May 2020 with the MedDRA lower level terms ‘stutter’ and ‘stuttering.’ The association between a drug and the occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (ROR) were calculated with 95% confidence intervals. Results: In total, 724 notifications were identified using the MedDRA terms selected. The main drugs implicated were methylphenidate (ROR = 19.58; 95% CI: 13.3–28.8), topiramate (ROR = 12.5; 95% CI: 7.1–22.1), olanzapine (ROR = 12; 95% CI: 8–17.9) and golimumab (ROR = 10.2; 95% CI: 5.5–19.1). Conclusions: When stuttering occurs in a patient treated by drugs affecting neurotransmission, a drug-induced origin of the stutter should be considered.


  • Amoxicillin‐induced crystal nephropathy: A nationwide French pharmacovigilance databases study

    by Laure Thomas, Christine Le Beller, Thierry Trenque, Joëlle Michot, Marie Zenut, Emmanuel Letavernier, Nicolas Mongardon, Dominique Vodovar

    Aims: Amoxicillin (AMX)‐induced crystal nephropathy (AICN) is a rarely reported adverse drug reaction (ADR) but its increase has been recently reported in the Paris area. Our aim was to investigate the incidence, characteristics and outcome of AICN in France.Methods: Retrospective analysis of all AICN cases reported to the French National Pharmacovigilance Database and the Marketing Authorization Holders Pharmacovigilance Database. AICN notification rate was compared to intravenous AMX and AMX–clavulanate sales.Results: In total, 101 AICN cases were included. Intravenous AMX/AMX–clavulanate was prescribed as surgical prophylaxis (32 surgical patients) or to treat infection (69 medical patients). AKI KDIGO stage 3 was observed in 70 patients and 24/70 patients required renal replacement therapy and/or intensive care unit admission. The annual notification rate of AICN was increased by a factor of 13 since 2010 (6 [0;7] and 77 [24;111] cases per 100 000 patient‐years of exposure, before and after 2010 respectively; P < .001). In surgical patients, the increase in AICN has been reported since 2010 and was mainly related to inadequate AMX administration. In medical patients, the increase in AICN was observed since 2014. After 2014, medical patients were older (67 [42;77] vs 74 years [64;84] respectively; P < .05) and were treated more frequently for endocarditis (0/20 vs 15/49 respectively; P < .01). A contributing factor was observed or suspected in 62 patients.Conclusion: AICN is a severe ADR that dramatically increased in France since 2010. Assessment of AICN contributing factors and AMX drug monitoring in patients receiving high dose of AMX could reduce the risk of AICN.


  • Open Access

    Methylphenidate and stuttering

    by Thierry Trenque, Gwladys Claustre, Emmanuelle Herlem, Zoubir Djerada, Agathe Trenque, Aurore Morel, Brahim Azzouz

    Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder. Studies concerning stuttering occurring with MPH are contradictory. We investigated the association between MPH and stuttering. We analysed reports in the World Health Organization global individual case safety reports database, Vigibase, up to 31 December 2018, with the MedDRA preferred term “dysphemia” and the lower level terms “stutter” and “stuttering”. The association between exposure to MPH and occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (RORs) were calculated with 95% confidence intervals (CIs). In total, 2975 cases of dysphemia were reported, of which 46 reports were associated with MPH. For the Preferred Term “dysphemia”, the ROR was 7.3 (95% CI: 5.4–9.8). With the Lower Level Term “stuttering”, 584 cases were registered in the database of which 17 involved MPH. The ROR was 13.9 (95% CI: 8.6–22.5). This study found a signal for stuttering with MPH.


  • Impact pronostique de la concentration de 3-hydroxymyristate sur la survie des patients atteints de cirrhose alcoolique ou virale

    by L. Granconato, J.-P. Pais de Barros, T. Mouillot, L. Lagrost, B. Bernard-Chabert, G. Thieffin, J.-L. Jouve, J.-P. Bronowicki, C. Richou, V. Di Martino, et al.